MONOCLONAL ANTIBODIES, INC. – Trademark Portfolio

Entity Type: 03

MONOCLONAL ANTIBODIES, INC. holds 12 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 10 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 4 Nice Classification classes. The owner is based in MOUNTAIN VIEW, CA.

2319 CHARLESTON ROAD

MOUNTAIN VIEW, CA 94043

12 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

MONOCLONAL ANTIBODIES, INC.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (10 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

9
Computers & Electronics (1 filing)

Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does MONOCLONAL ANTIBODIES, INC. have?

MONOCLONAL ANTIBODIES, INC. has 12 U.S. trademarks filed with the USPTO.

What trademark classes does MONOCLONAL ANTIBODIES, INC. file in?

MONOCLONAL ANTIBODIES, INC. files trademarks across 4 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What is MONOCLONAL ANTIBODIES, INC.'s trademark registration success rate?

MONOCLONAL ANTIBODIES, INC. has a 0% trademark registration rate, with 0 out of 12 resolved applications resulting in successful registration. Currently, 0 applications are pending review.